955 Chesterbrook Boulevard
Suite 110
Chesterbrook, PA 19087
United States
610 354 8840
https://www.trevena.com
版塊: Healthcare
行業: Biotechnology
全職員工: 23
名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
---|---|---|---|---|
Ms. Carrie L. Bourdow | President, CEO & Chairman | 1.08M | 無 | 1963 |
Mr. Barry Shin | Executive VP, COO & CFO | 722.79k | 無 | 1972 |
Dr. Mark A. Demitrack M.D. | Senior VP & Chief Medical Officer | 741.35k | 無 | 1958 |
Dr. Howard A. Rockman M.D. | Scientific Founder, Consultant and Member of Scientific Advisory Board | 無 | 無 | 無 |
Mr. Joel Solomon | VP, General Counsel, Company Secretary & Chief Compliance Officer | 無 | 無 | 無 |
Mr. Michael Catalano | Vice President of Marketing | 無 | 無 | 無 |
Mr. Robert T. Yoder | Senior VP, Chief Business Officer & Head of Commercial Operations | 490.64k | 無 | 1966 |
Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV734, a small molecule G protein biased ligand of the MOR, which has completed phase I studies for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania.
截至 無 止,Trevena, Inc. 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中:無;董事會:無;股東權利:無;現金賠償:無。